Targeted small molecule inhibitors blocking the cytolytic effects of pneumolysin and homologous toxins
Umer Bin Abdul Aziz, Ali Saoud, Marcel Bermúdez, Maren Mieth, Amira Atef, Thomas Rudolf, Christoph Arkona, Timo Trenkner, Christoph Böttcher, Kai Ludwig, Angelique Hœlzemer, Andreas C. Hocke, Gerhard Wolber, Jörg Rademann
Abstract
Abstract Pneumolysin (PLY) is a cholesterol-dependent cytolysin (CDC) from Streptococcus pneumoniae , the main cause for bacterial pneumonia. Liberation of PLY during infection leads to compromised immune system and cytolytic cell death. Here, we report discovery, development, and validation of targeted small molecule inhibitors of PLY (pore-blockers, PB). PB-1 is a virtual screening hit inhibiting PLY-mediated hemolysis. Structural optimization provides PB-2 with improved efficacy. Cryo-electron tomography reveals that PB-2 blocks PLY-binding to cholesterol-containing membranes and subsequent pore formation. Scaffold-hopping delivers PB-3 with superior chemical stability and solubility. PB-3 , formed in a protein-templated reaction, binds to Cys428 adjacent to the cholesterol recognition domain of PLY with a K D of 256 nM and a residence time of 2000 s. It acts as anti-virulence factor preventing human lung epithelial cells from PLY-mediated cytolysis and cell death during infection with Streptococcus pneumoniae and is active against the homologous Cys-containing CDC perfringolysin (PFO) as well.